$CLGN News

COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION

COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR

COLLPLANT ANNOUNCES REVERSE SHARE SPLIT

CollPlant Biotechnologies Board Approves 1-For-10 Reverse Share Split, Effective September 4

COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS

CollPlant Biotechnologies Files Prospectus For Offering 31.047M Shares On Behalf Of Selling Shareholders

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT

CollPlant Biotechnologies Commences ~$2.6M Offering Of Ordinary Share, Warrants

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Q1 Adj. EPS $(0.21) Misses $(0.19) Estimate, Sales $73.000K Miss $1.100M Estimate

CollPlant Biotechnologies shares are trading lower after the company announced the termination of its development agreement with AbbVie.

CollPlant Biotechnologies shares are trading lower after the company announced the termination of its development agreement with AbbVie.

CollPlant Biotechnologies Announces Termination Of Development Agreement With AbbVie, Issues Letter to Shareholders, Will Reduce Headcount By 50%

CollPlant Biotechnologies (NASDAQ:CLGN) Stock Surges on Q4 Revenue Beat

CollPlant Biotechnologies shares are trading lower after the company reported worse-than-expected Q4 financial results.

CollPlant Biotechnologies Q4 Adj. EPS $(0.25) Misses $(0.19) Estimate, Sales $60.000K Miss $1.524M Estimate

CollPlant Biotechnologies Q4 Adj. EPS $(0.25) Misses $(0.19) Estimate, Sales $60.000K Miss $1.524M Estimate.

CollPlant Biotechnologies Receives Nasdaq Noncompliance Notice, Gets Time Through Sept. 21 To Regain Compliance

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler